C21H39O7P (434.2433)

LysoPA(0:0/18:2(9Z,12Z)) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).

LysoPA(18:2(9Z,12Z)/0:0)

{2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy}phosphonic acid

C21H39O7P (434.2433)

LPA(18:2(9Z,12Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293) [HMDB] LysoPA(18:2(9Z,12Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).

(2s)-2-[[(2s)-2-Acetamido-5-[[n-(Methylcarbamoyl)carbamimidoyl]amino]pentanoyl]-Methyl-Amino]-3-Phenyl-Propanoic Acid

2-{2-[(1-hydroxyethylidene)amino]-N-methyl-5-({[(methyl-C-hydroxycarbonimidoyl)amino]methanimidoyl}amino)pentanamido}-3-phenylpropanoate

C20H30N6O5 (434.2278)

11-(Dansylamino)undecanoic acid

11-((5-Dimethylaminonaphthalene-1-sulfonyl)amino)undecanoic acid

C23H34N2O4S (434.2239)

D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D003619 - Dansyl Compounds D004396 - Coloring Agents > D005456 - Fluorescent Dyes

Lexibulin

1-ethyl-3-[2-methoxy-4-[5-methyl-4-[[(1S)-1-pyridin-3-ylbutyl]amino]pyrimidin-2-yl]phenyl]urea

C24H30N6O2 (434.243)

Ribociclib

7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

C23H30N8O (434.2542)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

Lincomycin S

N,S-Didemethyl-N,S-diethyllincomycin

2-(10-Ethoxy-1,9-dihydroxy-4b,8,8-trimethyl-3,4-dioxo-5,6,7,8a,9,10-hexahydrophenanthren-2-yl)propyl acetate

C24H34O7 (434.2304)

DAUDA

11-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]-undecanoic acid

C23H34N2O4S (434.2239)

6-[(3E,6E)-2,5-dihydroxy-4,6-dimethyl-7-(1,2,4-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-4-yl)hepta-3,6-dien-2-yl]-4-methoxy-3,5-dimethylpyran-2-one

C24H34O7 (434.2304)

omriolide B

C24H34O7 (434.2304)

(all-Z)-5,7-dihydroxy-2-nonadeca-4,7,10,13,16-pentenyl-chromone|5,7-dihydroxy-2-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaen-1-yl)-4H-chromen-4-one|5,7-dihydroxy-2-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaenyl)-4H-chromen-4-one|5,7-dihydroxy-2-(4Z,7Z,10Z,13Z,16Z-nonadecapentaenyl)chromone

(all-Z)-5,7-dihydroxy-2-nonadeca-4,7,10,13,16-pentenyl-chromone|5,7-dihydroxy-2-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaen-1-yl)-4H-chromen-4-one|5,7-dihydroxy-2-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaenyl)-4H-chromen-4-one|5,7-dihydroxy-2-(4Z,7Z,10Z,13Z,16Z-nonadecapentaenyl)chromone

Rosthornin B

[(1R,4R,5R,9R,10R,13R)-11-acetyloxy-2,13-dihydroxy-5,9-dimethyl-14-methylidene-15-oxo-5-tetracyclo[11.2.1.01,10.04,9]hexadecanyl]methyl acetate

NCGC00381173-01!13-oxo-7-[3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxytetradecanoic acid

C21H38O9 (434.2516)

6-[(4E,6E)-2,3-dihydroxy-4,6-dimethyl-7-(1,2,4-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-4-yl)hepta-4,6-dien-2-yl]-4-methoxy-3,5-dimethylpyran-2-one

NCGC00380375-01!6-[(4E,6E)-2,3-dihydroxy-4,6-dimethyl-7-(1,2,4-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-4-yl)hepta-4,6-dien-2-yl]-4-methoxy-3,5-dimethylpyran-2-one

C24H34O7 (434.2304)

C24H34O7_{(1R,4aR,5S,6R,8S,8aR)-8-Acetoxy-5,6-dimethyl-5-[(2S,3aS,6aS)-2,3,3a,6a-tetrahydrofuro[2,3-b]furan-2-yl]octahydro-8aH-spiro[naphthalene-1,2-oxiran]-8a-yl}methyl acetate

NCGC00347625-02_C24H34O7_{(1R,4aR,5S,6R,8S,8aR)-8-Acetoxy-5,6-dimethyl-5-[(2S,3aS,6aS)-2,3,3a,6a-tetrahydrofuro[2,3-b]furan-2-yl]octahydro-8aH-spiro[naphthalene-1,2-oxiran]-8a-yl}methyl acetate

C24H34O7 (434.2304)

3-Deoxycaryoptinol

C24H34O7 (434.2304)

(2R)-2-{2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]acetamido}-3-sulfanylpropanoic acid

C17H34N6O5S (434.2311)

Ac-DL-Arg(CONHMe)-DL-N(Me)Phe-OH

C20H30N6O5 (434.2278)

3-acetyleriocasin C, (rel)-

C24H34O7 (434.2304)

A natural product found in Isodon eriocalyx.

Maoesin E, (rel)-

A 1-acylglycerone 3-phosphate in which the acyl group is specified as oleoyl.

LysoPA(18:2(9Z,12Z)/0:0)

C21H39O7P (434.2433)

2-Linoleoyl-glycero-3-phosphate

C21H39O7P (434.2433)

{"Ingredient_id": "HBIN012272","Ingredient_name": "6beta-hydroxy-7-alpha-ethoxy-16-acetoxyroyleanone","Alias": "NA","Ingredient_formula": "C24H34O7","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "31191","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

adenanthin f

C24H34O7 (434.2304)

{"Ingredient_id": "HBIN014677","Ingredient_name": "adenanthin f","Alias": "NA","Ingredient_formula": "C24H34O7","Ingredient_Smile": "CC(=O)OC1CC2C(C(CC(C2(C3C14CC(CC3O)C(=C)C4=O)C)O)OC(=O)C)(C)C","Ingredient_weight": "434.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "610","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10873754","DrugBank_id": "NA"}

adenanthin g

C24H34O7 (434.2304)

C28H34O4 (434.2457)

(1s,2s,5r,7r,8s,9r,10s,11r,15s)-9-(acetyloxy)-10,15-dihydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-7-yl acetate

C24H34O7 (434.2304)